Basics Corcept Therapeutics Incorporated Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol. IPO Date: April 14, 2004 Sector: Healthcare Industry: Pharma Market Cap: $9.06B Activated in VL: True Average Daily Range Avg Daily Range: $0.30 | 2.78% Avg Daily Range (30 D): $1.51 | 2.05% Avg Daily Range (90 D): $1.61 | 2.16% Institutional Daily Volume Avg Daily Volume: .48M Avg Daily Volume (30 D): .51M Avg Daily Volume (90 D): .65M Trade Size Avg Trade Size (Sh.): 98 Avg Trade Size (Sh.) (30 D): 37 Avg Trade Size (Sh.) (90 D): 38 Institutional Trades Total Inst.Trades: 4,479 Avg Inst. Trade: $2.85M Avg Inst. Trade (30 D): $5.31M Avg Inst. Trade (90 D): $5.66M Avg Inst. Trade Volume: .1M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $3.96M Avg Closing Trade (30 D): $8.35M Avg Closing Trade (90 D): $9.4M Avg Closing Volume: 139.09K     News May 8, 2025 @ 5:00 PM High- and Low-Grade Serous Ovarian Cancer Market i... Source: Delveinsight Dec 11, 2024 @ 6:00 PM Alcohol Use Disorder Market Set for Remarkable Gro... Source: Delveinsight Sep 19, 2024 @ 7:36 PM Corcept Moves 6.5% Higher: Will This Strength Last... Source: Zacks Sep 3, 2024 @ 8:29 PM Corcept Shares Rise More Than 45% in Six Months: H... Source: Zacks Aug 6, 2024 @ 10:20 AM Should You Invest in the First Trust NYSE Arca Bio... Source: Zacks Investment Research Financials   TTM Q3 2025 Q2 2025 Basic EPS $1 $.19 $.33 Diluted EPS $.87 $.16 $.29 Revenue $ 741.17M $ 207.64M $ 194.43M Gross Profit $ 727.78M $ 203.04M $ 191M Net Income / Loss $ 106.11M $ 19.67M $ 35.15M Operating Income / Loss $ 65.57M $ 10.22M $ 26.68M Cost of Revenue $ 13.39M $ 4.6M $ 3.43M Net Cash Flow $ -12.15M $ 22.39M $ 12.93M PE Ratio 98.97